Literature DB >> 8299662

The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers.

D Allen1, H V Curran, M Lader.   

Abstract

The effects of single doses of CL284,846 (20 mg), lorazepam (2 mg) and placebo on psychomotor performance, memory function and subjective feelings were assessed in 12 normal, healthy male volunteers. Each subject received each treatment in balanced order and a minimum of 6 days was left between treatments. The subjects performance on a comprehensive battery of tests of psychomotor performance, memory function and subjective ratings was assessed pre-treatment and at 1, 3 and 5 h post-treatment. In general, the effects of CL284,846 on memory were similar to those of lorazepam at 1 h post-treatment but, recovery was rapid with CL284,846. Impairments induced by lorazepam persisted throughout the post-drug testing sessions. This pattern of effects was repeated across most of the variables tested. However, at 1 h, CL284,846 produced less marked psychomotor impairment than lorazepam. The results of this study suggest that CL284,846 is a safe, rapid acting and effective sedative with some clear advantages over lorazepam with respect to unwanted cognitive and psychomotor impairments.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8299662     DOI: 10.1007/BF00265947

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  Benzodiazepines and human memory: a review.

Authors:  M M Ghoneim; S P Mewaldt
Journal:  Anesthesiology       Date:  1990-05       Impact factor: 7.892

2.  The effects of repeated doses of clomipramine and alprazolam on physiological, psychomotor and cognitive functions in normal subjects.

Authors:  D Allen; H V Curran; M Lader
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  A comparative study of the interaction of alcohol with alpidem, lorazepam and placebo in normal subjects.

Authors:  D Allen; A Baylav; M Lader
Journal:  Int Clin Psychopharmacol       Date:  1988-10       Impact factor: 1.659

4.  Mental rotation of three-dimensional objects.

Authors:  R N Shepard; J Metzler
Journal:  Science       Date:  1971-02-19       Impact factor: 47.728

5.  Differentiating the sedative, psychomotor and amnesic effects of benzodiazepines: a study with midazolam and the benzodiazepine antagonist, flumazenil.

Authors:  H V Curran; B Birch
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

6.  A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic.

Authors:  B Beer; J R Ieni; W H Wu; D Clody; P Amorusi; J Rose; T Mant; J Gaudreault; A Cato; W Stern
Journal:  J Clin Pharmacol       Date:  1994-04       Impact factor: 3.126

7.  Differential amnesic properties of benzodiazepines: a dose-response comparison of two drugs with similar elimination half-lives.

Authors:  H V Curran; W Schiwy; M Lader
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 8.  Allosteric modulatory centers of transmitter amino acid receptors.

Authors:  E Costa
Journal:  Neuropsychopharmacology       Date:  1989-09       Impact factor: 7.853

9.  Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood.

Authors:  H V Curran; F Schifano; M Lader
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

10.  Sedative-hypnotics and human performance.

Authors:  L C Johnson; D A Chernik
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

View more
  11 in total

1.  Pharmacokinetic-pharmacodynamic analysis of mnesic effects of lorazepam in healthy volunteers.

Authors:  O Blin; A Jacquet; S Callamand; E Jouve; M Habib; D Gayraud; A Durand; B Bruguerolle; P Pisano
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  Effects of the amnesic drug lorazepam on complete and partial information retrieval and monitoring accuracy.

Authors:  M Izaute; E Bacon
Journal:  Psychopharmacology (Berl)       Date:  2006-08-17       Impact factor: 4.530

Review 3.  Benefit-risk assessment of zaleplon in the treatment of insomnia.

Authors:  Joseph Barbera; Colin Shapiro
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  Zaleplon: a review of its use in the treatment of insomnia.

Authors:  M Dooley; G L Plosker
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 5.  New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.

Authors:  Mario Giovanni Terzano; Mariano Rossi; Vincenzo Palomba; Arianna Smerieri; Liborio Parrino
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

6.  A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening.

Authors:  P Danjou; I Paty; R Fruncillo; P Worthington; M Unruh; W Cevallos; P Martin
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 7.  Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone.

Authors:  David R Drover
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  The Importance of Residual Effects When Choosing a Hypnotic: The Unique Profile of Zaleplon.

Authors:  Gary K. Zammit; Jeffrey A. Kramer
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-04

9.  Effects of lorazepam on deductive reasoning.

Authors:  S Pompéia; G M Manzano; M Pradella-Hallinan; O F A Bueno
Journal:  Psychopharmacology (Berl)       Date:  2007-07-11       Impact factor: 4.530

10.  Benzodiazepines and semantic memory: effects of lorazepam on the Moses illusion.

Authors:  Marie Izaute; Laurence Paire-Ficout; Elisabeth Bacon
Journal:  Psychopharmacology (Berl)       Date:  2003-11-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.